Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR20013 vs palonosetron for chemotherapy-induced nausea and vomiting in moderate emetic risk
NCT06554184Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rolapitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Complete response rate in the delayed phase. Started Sep 2024; status: completed.
02
Drugs
rolapitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06554184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554184.